April 21, 2025 – The FDA just approved the popular drug Dupixent for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a long-lasting itchy skin condition, when regular ...

The US Food and Drug Administration (FDA) has granted approval to Dupixent or dupilumab for the treatment of chronic spontaneous urticaria (CSU) in adults and adolescents who are aged 12 years or ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older ...

The condition is linked to Type 2 inflammation, which Dupixent helps target by blocking certain immune signaling pathways. The injection is already approved for CSU in several other countries ...

The most common adverse reaction reported with dupilumab in all 3 CUPID trials were injection site reactions. “Dupixent is the first new targeted treatment for chronic spontaneous urticaria ...

In pooled data from all three trials, the most common adverse event (≥2%) more frequently observed in patients on Dupixent compared to placebo was injection site reactions. “CSU patients with ...

shown in the Dupixent development programme to be central drivers of the type 2 inflammation that plays a major role in multiple related diseases, including CSU. The drug, which is administered as a ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with chronic spontaneous urticaria. The approval is for patients 12 years and ...

“Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce ...